Holen Sie sich die Stockscreener-App
4.57
0.00%
0.00
Handel nachbörslich:
4.48
-0.09
-1.97%
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
Lantern Pharma secures EU patent for AI-driven cancer drug LP-284 - MSN
Lantern Pharma Inc. Recovery Likely Here’s What Data ShowsJuly 2025 Outlook & Daily Profit Focused Screening - sundaytimes.kr
Lantern Pharma shares fall 6.72% intraday despite positive clinical trial results. - AInvest
What is Lantern Pharma Inc.’s book value per share2025 Analyst Calls & Long Hold Capital Preservation Plans - newsyoung.net
Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses In Multiple Trials - Barchart.com
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates - BioSpace
Lantern Pharma Narrows Loss in Q2 - The Motley Fool
Lantern Pharma Narrows Loss in Q2 - Nasdaq
Lantern Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates | LTRN Stock News - GuruFocus
Short Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Rises By 109.5% - MarketBeat
Price momentum metrics for Lantern Pharma Inc. explainedHigh Confidence Strategy with Trend Alignment - Newser
Is Lantern Pharma Inc. meeting your algorithmic filter criteriaStable Profit Zone and Loss Control Analysis - Newser
What data driven models say about Lantern Pharma Inc.’s futureFree Trade Setups With Clear Risk Limits - Newser
Can volume confirm reversal in Lantern Pharma Inc.Alpha Stock Picks with Chart Confirmation - Newser
Automated trading signals detected on Lantern Pharma Inc.Free Entry Points For Growing Stocks - Newser
Os Therapies Incorporated shares rise 1.14% intraday after Lantern Pharma's subsidiary cleared IND application for GBM trial. - AInvest
Lantern Pharma Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Lantern Pharma Inc. Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule - citybuzz -
Lantern Pharma (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations - Barchart.com
Lantern Pharma (LTRN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Lantern Pharma Announces Release of Advanced AI Module for Blood-Brain Barrier Permeability Prediction - AI Insider
Nerdy Inc. shares rise 1.78% after-hours following Lantern Pharma's FDA clearance for GBM trial. - AInvest
How Lantern Pharma Inc. stock performs during market volatilityDaily Stock Forecast Powered by AI Tools - Newser
Lantern Pharma (NASDAQ: LTRN) Subsidiary Starlight Therapeutics Cleared by FDA to Begin GBM Combination Trial - Barchart.com
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed - openPR.com
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed Clinical Trials And FDA-Approved Therapies Review By Delveinsight Dnatrix, Lantern Pharma, Vyriad, Chimerix, Pfizer, Takeda Pharmaceuticals - Menafn
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | DNAtrix, Lantern Pharma, Vyriad, Chimerix, Pfizer, Takeda Pharmaceuticals - Barchart.com
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial | LTRN Stock News - GuruFocus
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U - GuruFocus
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial - Business Wire
Lantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy - Barchart.com
Lantern Pharma completes Japanese enrolment for lung cancer drug trial - Mugglehead Magazine
Lantern Pharma schließt japanische Rekrutierung für Lungenkrebsmedikamentstudie ab - Mugglehead Magazine
Real Time Chart Alerts Flash Bullish on Lantern Pharma Inc.Swing Trade Plans Emphasize Risk Management - metal.it
Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™ - 01net
Lantern Pharma Announces Public Release of AI Module for Blood-Brain Barrier Permeability Prediction - AInvest
Lantern Pharma Unveils PredictBBB.ai With 94% Accuracy, Revolutionizing CNS Drug Development Through Real-Time AI - 富途牛牛
How strong is Lantern Pharma Inc. company’s balance sheetNavigate market volatility with smart strategies - Jammu Links News
How does Lantern Pharma Inc. generate profit in a changing economyGame-changing returns - Jammu Links News
Is Lantern Pharma Inc. stock overvalued or undervaluedExceptional growth trajectory - Jammu Links News
What are analysts’ price targets for Lantern Pharma Inc. in the next 12 monthsUnlock your trading potential today - Jammu Links News
How volatile is Lantern Pharma Inc. stock compared to the marketAchieve rapid capital gains with smart investing - Jammu Links News
What makes Lantern Pharma Inc. stock price move sharplyRapid wealth multiplication - Jammu Links News
Is it the right time to buy Lantern Pharma Inc. stockBuild a portfolio that stands the test of time - Jammu Links News
What is the dividend policy of Lantern Pharma Inc. stockStay ahead with advanced stock screening tools - Jammu Links News
Pharma stock good to short now? - AInvest
Lantern Pharma Appoints Dr. Schalop to Board - MSN
Lantern Pharma Inc. Recovery Gathers Momentum on Chart SignalsWatchlist for Smart Swing Trading Updated - metal.it
What is Lantern Pharma Inc. company’s growth strategyBeginner Investor Report With Low Risk - Jammu Links News
Lantern Pharma concludes patient enrolment for trial of LP-300 in Japan - Yahoo Finance
Lantern Pharma (NASDAQ: LTRN) Completes Targeted Enrollment for Phase 2 HARMONIC Trial in Japan - Barchart.com
Lantern Pharma's Strategic Expansion in Japan: A Catalyst for Near-Term Stock Appreciation - AInvest
Lantern Pharma (LTRN) Concludes Phase 2 Trial Enrollment in Japa - GuruFocus
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):